Transcenta’s Promising Anti-Tumor Breakthrough in Breast Cancer

Transcenta Holding Limited (HK:6628) has released an update.

Transcenta Holding Limited has unveiled promising preclinical results of its novel anti-tumor LIV-1 targeting ADCs, ADC-1 and ADC-2, which showcased significantly higher tumor regression in triple-negative breast cancer models compared to traditional ADCs. These antibodies, utilizing a proprietary site-specific Topoisomerase I Inhibitor payload, demonstrated strong efficacy and potential as next-generation therapeutic agents. This advancement could mark a significant step forward in the treatment of aggressive breast cancer types and other solid tumors.

For further insights into HK:6628 stock, check out TipRanks’ Stock Analysis page.